Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial (vol 9, pg 743, 2021)

被引：0
|
作者：
Heerspink, H. J. L.
Jongs, N.
Chertow, G. M.
机构：
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2022年 / 10卷 / 10期
关键词：
D O I：
10.1016/S2213-8587(22)00223-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E10 / E10
页数：1
相关论文
共 50 条
  • [21] A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes
    Bakris, George L.
    Ruilope, Luis M.
    Anker, Stefan D.
    Filippatos, Gerasimos
    Pitt, Bertram
    Rossing, Peter
    Fried, Linda
    Roy-Chaudhury, Prabir
    Sarafidis, Pantelis
    Ahlers, Christiane
    Brinker, Meike
    Joseph, Amer
    Lawatscheck, Robert
    Agarwal, Rajiv
    KIDNEY INTERNATIONAL, 2023, 103 (01) : 196 - 206
  • [22] Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials
    Moura, F.
    Wiviott, S.
    Chertow, G.
    Dwyer, J.
    Gause-Nilsson, I
    Johansson, P.
    Langkilde, A.
    McMurray, J.
    Mosenzon, O.
    Raz, I
    Rossing, P.
    Wheeler, D.
    Sabatine, M.
    Heerspink, H.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2407 - 2407
  • [23] Effect of metformin on kidney function in patients with type 2 diabetes mellitus and moderate chronic kidney disease
    Hsu, Wei-Hao
    Hsiao, Pi-Jung
    Lin, Pi-Chen
    Chen, Szu-Chia
    Lee, Mei-Yueh
    Shin, Shyi-Jang
    ONCOTARGET, 2018, 9 (04) : 5416 - 5423
  • [24] Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus
    Shibata, Ryo
    Taguchi, Kensei
    Kaida, Yusuke
    Fukami, Kei
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2023, 27 (01) : 44 - 53
  • [25] Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus
    Ryo Shibata
    Kensei Taguchi
    Yusuke Kaida
    Kei Fukami
    Clinical and Experimental Nephrology, 2023, 27 : 44 - 53
  • [26] Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial
    van Ruiten, Charlotte C.
    Van der Aart-van der Beek, Annemarie B.
    IJzerman, Richard G.
    Nieuwdorp, Max
    Hoogenberg, K.
    van Raalte, Daniel H.
    Heerspink, Hiddo J. L.
    DIABETES OBESITY & METABOLISM, 2021, 23 (08): : 1851 - 1858
  • [27] Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial (vol 12, pg 39, 2024)
    Staplin, N.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (11): : e20 - e20
  • [28] Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
    Akihiko Koshino
    Brendon L. Neuen
    Niels Jongs
    Carol Pollock
    Peter J. Greasley
    Eva-Marie Andersson
    Ann Hammarstedt
    Cecilia Karlsson
    Anna Maria Langkilde
    Takashi Wada
    Hiddo J.L. Heerspink
    Cardiovascular Diabetology, 22
  • [29] Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
    Koshino, Akihiko
    Neuen, Brendon L.
    Jongs, Niels
    Pollock, Carol
    Greasley, Peter J.
    Andersson, Eva-Marie
    Hammarstedt, Ann
    Karlsson, Cecilia
    Langkilde, Anna Maria
    Wada, Takashi
    Heerspink, Hiddo J. L.
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [30] Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials
    Gohda, Tomohito
    Murakoshi, Maki
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
12345